NO20170739A1 - Novel virus in Fish and Method for detection - Google Patents
Novel virus in Fish and Method for detection Download PDFInfo
- Publication number
- NO20170739A1 NO20170739A1 NO20170739A NO20170739A NO20170739A1 NO 20170739 A1 NO20170739 A1 NO 20170739A1 NO 20170739 A NO20170739 A NO 20170739A NO 20170739 A NO20170739 A NO 20170739A NO 20170739 A1 NO20170739 A1 NO 20170739A1
- Authority
- NO
- Norway
- Prior art keywords
- seq
- sequences
- sequence
- complementary
- nucleic acid
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title claims description 35
- 238000000034 method Methods 0.000 title claims description 20
- 238000001514 detection method Methods 0.000 title claims description 10
- 150000007523 nucleic acids Chemical group 0.000 claims description 44
- 230000000295 complement effect Effects 0.000 claims description 35
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 30
- 239000000523 sample Substances 0.000 claims description 29
- 239000002773 nucleotide Substances 0.000 claims description 24
- 125000003729 nucleotide group Chemical group 0.000 claims description 24
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 20
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 20
- 239000012472 biological sample Substances 0.000 claims description 16
- 238000012163 sequencing technique Methods 0.000 claims description 10
- 241000276599 Cyclopterus lumpus Species 0.000 claims description 9
- 108010041986 DNA Vaccines Proteins 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 229940021995 DNA vaccine Drugs 0.000 claims description 5
- 239000013598 vector Substances 0.000 claims description 5
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 229940124551 recombinant vaccine Drugs 0.000 claims description 4
- 238000010839 reverse transcription Methods 0.000 claims description 4
- 108010008038 Synthetic Vaccines Proteins 0.000 claims description 3
- 230000003321 amplification Effects 0.000 claims description 3
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 3
- 238000003752 polymerase chain reaction Methods 0.000 claims description 3
- 238000009007 Diagnostic Kit Methods 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 241000251468 Actinopterygii Species 0.000 description 24
- 235000019688 fish Nutrition 0.000 description 24
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 241000276603 Cyclopteridae Species 0.000 description 10
- 150000001413 amino acids Chemical group 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 150000002500 ions Chemical class 0.000 description 8
- 241001674048 Phthiraptera Species 0.000 description 6
- 241000277331 Salmonidae Species 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 241000710831 Flavivirus Species 0.000 description 5
- 241000710921 Infectious pancreatic necrosis virus Species 0.000 description 5
- 238000011529 RT qPCR Methods 0.000 description 5
- 230000004075 alteration Effects 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 229960005486 vaccine Drugs 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 238000003559 RNA-seq method Methods 0.000 description 3
- 241000338155 Tamana bat virus Species 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000005714 functional activity Effects 0.000 description 3
- 210000002816 gill Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 206010003445 Ascites Diseases 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241001386813 Kraken Species 0.000 description 2
- 241000973618 Labroides dimidiatus Species 0.000 description 2
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 2
- 241000544286 Vibrio anguillarum Species 0.000 description 2
- 241000711825 Viral hemorrhagic septicemia virus Species 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 238000009360 aquaculture Methods 0.000 description 2
- 244000144974 aquaculture Species 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000009313 farming Methods 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 125000001165 hydrophobic group Chemical group 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000007481 next generation sequencing Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 239000002096 quantum dot Substances 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229910001415 sodium ion Inorganic materials 0.000 description 2
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- 108020003589 5' Untranslated Regions Proteins 0.000 description 1
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
- 241000607534 Aeromonas Species 0.000 description 1
- 241000607525 Aeromonas salmonicida Species 0.000 description 1
- 241000607337 Aliivibrio logei Species 0.000 description 1
- 241001600138 Aliivibrio wodanis Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 241001611011 Caligus Species 0.000 description 1
- 241001428800 Cell fusing agent virus Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000693336 Ctenolabrus rupestris Species 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 241000710872 Dengue virus 3 Species 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 241000710781 Flaviviridae Species 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 238000009015 Human TaqMan MicroRNA Assay kit Methods 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 241000269951 Labridae Species 0.000 description 1
- 241000556695 Labrus bergylta Species 0.000 description 1
- 241001247234 Lepeophtheirus salmonis Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 238000007476 Maximum Likelihood Methods 0.000 description 1
- 241000098783 Neoparamoeba perurans Species 0.000 description 1
- 241000604447 Nucleospora cyclopteri Species 0.000 description 1
- 241000606860 Pasteurella Species 0.000 description 1
- 241000606580 Pasteurella sp. Species 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 241000520869 Pseudomonas anguilliseptica Species 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 229940022005 RNA vaccine Drugs 0.000 description 1
- 241000692569 Stylephorus chordatus Species 0.000 description 1
- 241000693337 Symphodus melops Species 0.000 description 1
- 102100021696 Syncytin-1 Human genes 0.000 description 1
- 241001542930 Tenacibaculum maritimum Species 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 206010047400 Vibrio infections Diseases 0.000 description 1
- 241001135139 Vibrio ordalii Species 0.000 description 1
- 241000510690 Vibrio tapetis Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000710772 Yellow fever virus Species 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000006229 amino acid addition Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 238000003766 bioinformatics method Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 208000003512 furunculosis Diseases 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 108700021021 mRNA Vaccine Proteins 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 230000005257 nucleotidylation Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- -1 organic solvents Chemical class 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 238000013081 phylogenetic analysis Methods 0.000 description 1
- 238000009372 pisciculture Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000011222 transcriptome analysis Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000009966 trimming Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 229940051021 yellow-fever virus Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Description
Novel virus in fish and a method for detection
The present invention relates to nucleic acid sequences isolated from a novel virus identified in lumpsucker and a method for detection of this virus, according to the preamble of the independent claims. The invention further provides primers and probes, a vector and a host cell, a DNA vaccine, a recombinant protein, a recombinant vaccine, an antibody and a diagnostic kit.
Background
Fish are an increasingly important source of food and income; global annual consumption is projected to rise from 110 million tons in 2010 to more than 200 million tons in 2030. However, the emergence of infectious diseases in aquaculture threatens production and may also impact wild fish populations.
Sea lice (Lepeophtheirus salmonis and Caligus spp.) are one of the major pathogens affecting global salmonid farming industry and have a significant impact in many areas. The annual loss has recently been estimated to €300 million and the aquaculture industry relays heavily on a few chemotherapeutants for lice control.
In Norwegian salmonid farming the use of cleaner fish has become more and more popular to prevent infections by sea lice. The most common species are the wrass species Ctenolabrus rupestris, Symphodus melops and Labrus bergylta, but also a large numbers of lumpsucker (Cyclopterus lumpus) are used. The lumpsuckers are particularly useful as they remain active at lower water temperatures.
Lumpsuckers are a good and popular solution for salmon lice control, and therefore they are both farmed and captured from the wild and set out in the salmonid cages, with the purpose to control sea lice. A single fish can eat over 300 lice a day. This has made this fish species very popular and there are more than 25 fish farms producing lumpsuckers in Norway, in 2016. By the expression "lumpsucker" is meant any species selected from the whole family of Cyclopteridae. The most preferred species is Cyclopterus lumpus.
As lumpsuckers are keeping the salmonids healthy, they are very valuable to the fish farming industry, even if they are not used for consumption themselves. Therefore it is important to keep them healthy, and known diseases in lumpsuckers are typically of bacterial origin. Furunculosis caused by atypical Aeromonas salmonicida is the most important pathogen, but also different vibrio species causing vibriosis such as Vibrio anguillarum are well known. Species like V.ordalii, V. splendidis, V. logei, V. wodanis, V. tapetis are also reported, in addition to Pseudomonas anguilliseptica and the recently reported Tenacibaculum maritimum and Pasteurella sp.
Previous examinations of captured cleaner fish have not detected viral infections as Viral haemorrhagic septicaemia virus (VHSV), Infectious Pancreatic Necrosis Virus (IPNV) or nodavirus. Salmonid alfavirus (SAV) has been reported from one farm. It is demonstrated that IPNV can infect lumpsuckers in laboratory studies.
During summer 2016 it was discovered a new disease among farmed lumpsuckers in Norway. Sick fish showed signs such as pale yellow liver with a rubberish texture, anaemic, open gills, and deformities on “sucker cup”. The disease has been observed in all stages of the life cycle.
In general heavy outbreaks are mainly observed in small fish, and are often observed in relation to handling, as transfer and/or vaccination. It is not clear how the virus is spreading, high mortality up to 50% can be observed in one tank while the neighbour tank remains healthy. The small fish die rapidly and often the whole tank has to be eradicated. In larger fish the virus seem to cause reduction in appetite and the fish stop eating, the liver loses its vital functions and the fish gets skinny and die. The virus has also been detected in broodfish kidney, but there were no clinical sign of disease.
There is therefore a need for a rapid method for identification of virus and a tool to monitor the production and avoid outbreak. Another object is to develop a vaccine and a further treatment to treat infected fish.
The invention
The invention relates to an isolated nucleic acid sequence originating from a virus in lumpsuckers having a sequence selected from the group consisting of SEQ ID No 1-14 or a sequence complementary to any of SEQ ID No 1-14, and variants thereof being at least 70% identical thereof.
According to one aspect, the isolated nucleic acid sequence is selected from the group of SEQ ID No 2-14, sequences being complementary to SEQ ID NO 2-14, and variants thereof being at least 70 % identical thereof.
The isolated nucleic acid sequence may be at least 80%, preferably 90%, more preferably 95 % identical with any of the sequences SEQ ID No 1-14, or any sequences being complementary to SEQ ID No 1-14.
In another aspect of the invention, it relates to a nucleic acid sequence of at least 10 nucleotides, wherein said sequence hybridizes specifically to a nucleic acid sequence having a sequence selected from the group consisting of SEQ ID NO 1-14, sequences being complementary to SEQ ID NO 1-14, and variants being at least 70 % identical with any of the sequences SEQ ID NO 1-14 and sequences being complementary to SEQ ID NO 1-14. Such a nucleic acid may be used as a primer for instance for PCR or a probe for instance for identification of a nucleic acid sequence or gene.
The nucleic acid sequence being at least 10 nucleotides long, may have a sequence selected from the group consisting of SEQ ID No 15-53, sequences being complementary to SEQ ID No 15-53, and variants being at least 70 % identical with any of the sequences SEQ ID NO 15-53 and sequences being complementary to SEQ ID NO 15-53. Further, the said nucleotide sequence may be at least 15 or at least 20 nucleotides long.
In another aspect the invention provides a primer or probe comprising a sequence of at least 10 nucleotides, having a sequence selected from the group consisting of SEQ ID NO 1-14, sequences being complementary to SEQ ID NO 1-14, and variants being at least 70 % identical with any of the sequences SEQ ID NO 1-14 and sequences being complementary to SEQ ID NO 1-14.
The primer or probe may be selected from the group consisting of SEQ ID NO 15-53, sequences being complementary to SEQ ID NO 15-53, and variants being at least 70 % identical with any of the sequences SEQ ID NO 15-53 and sequences being complementary to SEQ ID NO 15-53. In some aspects the primer may be 15 nucleotides or 20 nucleotides long.
The above said nucleic acid sequence being at least 10 nucleotides long, or the primer or probe, may be at least 80%, preferably 90%, more preferably 95 % identical with any of the sequences SEQ ID No 1-14, or any sequences being complementary to SEQ ID No 1-14.
According to another aspect of the invention, a method for detection of a virus in a biological sample is provided. The method comprises the following steps:
a) preparing a sample comprising nucleic acid sequences isolated from a biological sample for a reverse transcription reaction,
b) subjecting the mixture of a) to a polymerase chain reaction with a primer pair, wherein each primer of said primer pair comprises at least 10 nucleotides and hybridizes to a nucleic acid sequence selected from the group consisting of SEQ ID No 1-53, sequences being complementary to SEQ ID No 1-53, and variants being at least 70 % identical with any of the sequences,
c) determining whether the binding of the nucleotide sequences to nucleotide sequences in the biological sample and amplification of the sequence between them have occurred indicating the presence of virus in the sample tested.
In a preferred embodiment, the primers of the method above are selected from a group consisting for SEQ ID No 28-53.
In step b) of the method above, the primer pair may hybridize to a nucleic acid being at least 80%, preferably 90%, more preferred 95 % or 100 % identical with any of the sequences SEQ ID No 1-14, or any sequences being complementary to SEQ ID No According to another aspect of the invention, another method for detection of a virus in a biological sample is provided. The method comprises the following steps: a) preparing a sample comprising nucleic acid sequences isolated from a biological sample for a reverse transcription reaction,
b) sequencing the mixture of a), and
c) comparing the resulting sequence with a sequence selected of the group consisting of SEQ ID No 1-14, sequences being complementary to SEQ ID NO 1-14, wherein 70 % identity verifies the presence of virus in the biological sample tested.
In step c) of the method above, 80 %, 90%, 95% or 100 % identity may be required to confirm the presence of virus in the biological sample.
In a preferred embodiment, the sequencing of the mixture in the method above is performed by a method selected from the group consisting of Next Generation Sequencing, preferably Illumina (Solexa) sequencing, Roche 454 sequencing, Ion Torrent or SOLiD sequencing (Goodwin S, et al., (2016) Coming of age: Ten years of next-generation sequencing technologies. Nature reviews, Genetics, 17, 333-351).
The invention also relates to use of a nucleic acid sequence comprising at the least 10 contiguous nucleotides of any of the sequences 1-53, or 10 contiguous nucleotides being complementary of any of the sequences 1-53, for confirming the presence of the virus in a biological sample. In another aspect it is used a nucleic acid sequence having a sequence selected from the group consisting of SEQ ID NO 2-14, or sequences being complementary to the sequences of SEQ ID NO 2-14. In yet another embodiment it is used a nucleic acid sequence having a sequence selected from the group of SEQ ID No 1, or a sequence being complementary to the any of the sequences SEQ ID No 1.
Another aspect of the invention relates to a vector comprising nucleic acid sequences according to the present invention, and host cells comprising said vectors.
According to yet another aspect of the invention, DNA vaccines are provided comprising a nucleic acid sequence selected from the group consisting of SEQ ID No. 1-14, sequences being complementary to sequences of SEQ ID No 1-14, and variants thereof being at least 70% identical with any of the sequences SEQ ID No.
1-14 or sequences being complementary to the sequences of SEQ ID No 1-14. The identity is preferably based on the entire sequence length of the said isolated nucleic acid sequence.
The nucleic acid sequence of the DNA vaccine may be at least 80%, preferably 90%, more preferably 95 % identical with any of the sequences SEQ ID No 1-14, or any sequences being complementary to SEQ ID No 1-14.
Another aspect of the invention relates to recombinant proteins encoded by a nucleic acid sequence selected from the group consisting of SEQ ID No.1-14, and variants thereof being at least 70 % identical with any of the sequences SEQ ID No.1-14, preferably based on the entire sequence length of the said isolated nucleic acid sequence. In one aspect the amino acid sequence of the recombinant protein is given in SEQ ID No 54.
The present invention also provides a recombinant vaccine comprising at least one of the recombinant proteins according to the present invention.
Furthermore, according to another aspect of the invention, it is provided an antibody that recognises and binds to a recombinant protein according to the present invention.
Finally, the present invention relates to the use of the nucleic acid sequences having a sequences selected from the group consisting of SEQ ID NO 1-14, sequences being complementary to SEQ ID NO 1-14, and variants thereof being at least 70 % identical with any of these sequences, for the preparation of DNA vaccine, recombinant vaccine or a live recombinant microorganism.
The present invention relates to isolated nucleic acid sequences and variants thereof being at least 70% identical with the isolated nucleic acid sequences. The term "% identity" is to be understood to refer to the percentage of nucleotides that two or more sequences or fragments thereof contains that are the same. The term "at least 70 % identical" thus means that at least 70 % of the nucleotides over the entire sequences which are compared, are identical. A specified percentage of nucleotides can be referred to as e.g. 70% identical, 80% identical, 85% identical, 90% identical, 95% identical, 99% identical or more over a specified region when compared and aligned for maximum correspondence. The skilled person will acknowledge that various means for comparing sequences are available.
The term "variants thereof" used in respect of the nucleic acid sequences and recombinant proteins according to the present invention, is to be understood to encompass nucleic acid sequences and recombinant proteins that only differs from the isolated sequences SEQ ID No.1-54 by way of some amino acid or nucleotide additions, deletions or alteration that have little effect, if any, on the functional activity of the claimed sequences. The skilled person will acknowledge that modifications of a protein coding nucleotide sequence may be introduced which does not alter the amino acid sequence, e.g. the substitution of a nucleotide resulting in that the triplett affected by the substitution still codes for the same amino acid. Such alterations may be introduced to adapt the nucleic acid sequence to the codons preferably used by a host cell and thus to enhance the expression of a desired recombinant protein.
Furthermore, the addition of nucleic acid sequences coding polypeptides which facilitates purification may be added without affecting the activity of the resulting recombinant protein.
The skilled person will further acknowledge that also alterations of the nucleic acid sequence resulting in modifications of the amino acid sequence of the recombinant protein it codes may have little, if any, effect on e.g. the proteins ability to induce protection against the virus if the alteration does not have any impact on the resulting three dimensional structure of the recombinant protein. For example, a codon for the amino acid alanine, a hydrophobic amino acid, may be substituted by a codon encoding another less hydrophobic residue, such as glycine, or a more hydrophobic residue, such as valine, leucine, or isoleucine. Similarly, changes which result in substitution of one negatively charged residue for another, such as aspartic acid for glutamic acid, or one positively charged residue for another, such as lysine for arginine, can also be expected to produce a recombinant protein with substantially the same functional activity as the protein encoded by the nucleotide sequences SEQ ID No.1-53 and thus to be expected to constitute a biologically equivalent product. Nucleotide changes which result in alteration of the N-terminal or C-terminal portions of the protein molecule would also not be expected to alter the functional activity of the protein. Each of the proposed modifications is well within the routine skills in the art, as is determination of retention of biological activity of the encoded products. Therefore, where the terms "nucleic acid sequences of the invention" or "recombinant protein of the invention" are used in either the specification or the claims each will be understood to encompass all such modifications and variations which result in the production of a biologically equivalent protein.
Thus, the present invention encompasses recombinant proteins and variants thereof which differ in respect of amino acid substitutions, addition or deletions compared with the protein of SEQ ID No 54, and proteins being encoded by the sequence SEQ ID No.1-53.
The primers and probes according to the present invention, will hybridize under stringent conditions with the sequence in question. The term “hybridizing under stringent conditions” refers to conditions of high stringency, i.e. in term of temperature, ionic strength, and the presence of other compounds such as organic solvents, under which nucleic acid hybridizations are conducted. With “high stringency” conditions, nucleic acid base pairing will occur only between nucleic acids having a high frequency of complementary base sequences. Stringent hybridization conditions are known to the skilled person (see e.g. Green M. R., Sambrook, J., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press; 4th edition, 2012). The precise conditions for stringent hybridization are typically sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures than shorter sequences. Generally, stringent conditions are selected to be about 5°C. lower than the thermal melting point (Tm) for the specific sequence at a defined ionic strength and pH. The Tm is the temperature (under defined ionic strength, pH and nucleic acid concentration) at which 50% of the probes complementary to the target sequence hybridize to the target sequence at equilibrium. Since the target sequences are generally present at excess, at Tm, 50% of the probes are occupied at equilibrium. Typically, stringent conditions will be those in which the salt concentration is less than about 1.0 M sodium ion, typically about 0.01 to 1.0 M sodium ion (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30°C. for short probes, primers or oligonucleotides (e.g., 10 nt to 50 nt) and at least about 60°C. for longer probes, primers and oligonucleotides. Stringent conditions may also be achieved with the addition of destabilizing agents, such as formamide.
The terms "antigen" when used in connection with the present invention is to be understood to refer to a recombinant protein or fragment thereof according to the invention being able to induce protection against the virus in fish or to be able to bind to an antibody which recognise and bind to the virus.
The term "vaccine" as used herein refers to a material that can produce an immune response that blocks the infectivity, either partially or fully, of an infectious agent, which in respect of the present invention is the virus affecting fish such as e.g. salmonids. Thus, when administering to a fish, the vaccines of the invention is immunised against the disease caused by the virus. The immunising component of the vaccine may be e.g. DNA as in a DNA vaccine, RNA as in a RNA vaccine, a recombinant protein or fragment thereof according to the present invention, or a live recombinant microorganism.
The present invention also provides short nucleotide sequences having a length of at least 10 nucleotides. These sequences may be primers or probes useful in polymerase chain reaction techniques to be used as diagnostic tools. The terms "primer" and "probes" as used herein refers to an oligonucleotide either naturally occurring or produced synthetically which is significantly complementary to a virus target sequence and thus capable of hybridizing to nucleic acid sequences of the present invention. When a primer pair is used, it is generally one forward and one reverse primer, and the sequence between the primers will be multiplied during a PCR. This is well known to a skilled person, and he/she would know which primers constitute a suitable pair. The amplified sequence may be labelled to facilitate detection, e.g. using fluorescent labels on a probe, or other label means well known to the skilled person.
Brief description of the figures
Figure 1 shows the genomic sequence of the Virus (LV) corresponding to SEQ ID No. 1.
Figure 2 shows the genomic sequence of LV1 corresponding to SEQ ID No.2 Figure 3 shows the genomic sequence of LV2 corresponding to SEQ ID No.3 Figure 4 shows the genomic sequence of LV3 corresponding to SEQ ID No.4 Figure 5 shows the genomic sequence of LV4 corresponding to SEQ ID No.5 Figure 6 shows the genomic sequence of LV5 corresponding to SEQ ID No.6 Figure 7 shows the genomic sequence of LV6 corresponding to SEQ ID No.7 Figure 8 shows the genomic sequence of LV7 corresponding to SEQ ID No.8 Figure 9 shows the genomic sequence of LV8 corresponding to SEQ ID No.9 Figure 10 shows the genomic sequence of LV9 corresponding to SEQ ID No.10 Figure 11 shows the genomic sequence of LV10 corresponding to SEQ ID No.11 Figure 12 shows the genomic sequence of LV11 corresponding to SEQ ID No.12 Figure 13 shows the genomic sequence of LV12 corresponding to SEQ ID No.13, Figure 14 shows the genomic sequence of LV13 corresponding to SEQ ID No.14, and
Figure 15 shows the amino acid sequences of SEQ ID No.1, corresponding to SEQ ID NO 54.
Figure 1 shows the genomic sequence of the novel virus identified in lumpsuckers. Figure 2 shows an important part of the genome, used to isolate and identify lumpsucker probe 1 (probe LV1) and forward and revers lumpsucker primers 1 (forward and revers primers LV1), as shown in table 2-4 below. Figures 2-14 shows corresponding parts used to isolate and identify probes and primers LV2-LV13.
Examples
Tissue:
RNA sequencing and virus detection
Samples from fish were collected from fish with clinical signs of disease (pale yellow liver, pale heart, pale gills, ascites in the abdominal cavity and some wounds in the abdominal region). The samples were tested by Real Time qPCR for known diseases in lumpsucker; Infectious Pancreatic Necrosis Virus (IPNV), Paramoeba perurans (AGD), Nucleospora cyclopteri, atypical Aeromonas salmonicidae, Pasteurella sp and Vibrio anguillarum. All samples except one, were negative on all tests. Two samples from the same randomly chosen fish, which tested negative on all other tests, were chosen for further analysis.
Tissue preparation, RNA isolation and analysis
RNA was extracted from kidney and liver tissue samples using RNAeasy Universal kit (Qiagen) on an automated system at the PatoGen Analyses AS accredited commercial laboratory. The RNA quality and concentration of the samples were assessed with the Agilent 2100 Bioanalyzer (Agilent Technologies) and the Qubit 3.0 Fluorometer (Thermo Fischer scientific) using the RNA 6000 Pico Kit (Agilent) and the Qubit HS Assay kit (Thermo Fischer Scientific).
Library preparation and RNA sequencing with Ion Torrent S5
420 to 480 µg of total RNA from the tissue samples was used as starting input for each of two RNA sequencing library preparations. The total RNA of each of the samples was treated with RiboMinus TM Eukaryote Kit v2 (Thermo Fischer Scientific) to remove ribosomal RNA. The rRNA-depleted RNA was fragmented and libraries were constructed using the Ion Total-RNA Seq Kit v2 (Thermo Fischer Scientific). Each library were bar-coded and further quantified with qRT-PCR.
Using the Ion Chef and the Ion 520<TM>and Ion 530<TM>kit Chef (Thermo Fischer Scientific), the library templates were clonally amplified on Ion Sphere Particles, loaded into two 530 Chips and sequenced on the Ion Torrent S5 (Thermo Fischer Scientific).
Description of bioinformatics analysis
Over 20 million reads were generated for two different whole transcriptome analysis samples. BAM-files were converted to FASTQ files using SAMTOOLS fastq command and we applied our in-house pathogen detection pipeline on the reads. Our approach utilizes publically available research tools.
First, reads were first trimmed 25bp in both the 5’ and 3’ end, and short reads (<50 bps) were removed using seqtk (https://github.com/lh3/seqtk). Reads mapping to the Stickleback genome were then removed using Kraken (using Kraken (Wood and Salzberg, 2014), before sequence construction with SPADES using the remaining reads (Bankevich et al., 2012). The resulting scaffold sequences were then tested for complementarity with known sequences using blastn and blastx algorithms against the Swiss-Prot and nt databases, respectively.
Several sequences in both samples which were chosen above, matched partly to members of the flaviviridae family (Cell fusing agent virus, Yellow fever virus, Dengue virus 3 and Tamana bat virus). To extend the length of the sequence we merged both samples and did sequence construction on this merged sample. The final genome were generated by aligning generated sequences, predicting ORFs and performed BLAST searches, with the assumption that long ORFs and complementarity with flaviviruses were indicative of correct sequence and reading frame. Final trimming of the UTRs were done based on read coverage differences.
The final genome is 10.7 Kbs, and divided into the following sections;
Bases 1-169; 5’UTR
Bases 170-10,615; CDS (3482 aa)
Bases 10,616-10,760; 3’UTR
Notably, BLASTX search of 4 evenly sized parts of the sequence matches different flavivirus proteins (envelope protein, NS3 and NS5). To further assess sequence similarity with different flaviviruses, we downloaded representative sequences of flaviviruses, and performed a maximum likelihood phylogeny (using neighbour joining and Jukes Cantor as the substitution model, and 100 bootstraps), using hepatitis virus C as the outgroup. This analysis revealed that the sequence we obtained was most similar to the sequence of Tamana Bat Virus. Also, phylogenetic analyses cluster the sequence most closely to the flavivirus Tamana Bat Virus.
Based on this, the novel identified virus is probably a Flavi virus.
Real Time PCR
To validate if the tentative virus, in the following referred to as LV, could be disease causing we designed a qPCR-assay in the presumptive polymerase region of the sequence using forward and reverse primers (LV1-F and LV-R table 3 and 4), and a minor groove binding (MGB) probe (LV1-P) labelled with 6-FAM. The primers were designed using the software Primer Express 3.0.1 (Thermo Fischer Scientific).
Secondary structures and the possibility of primer dimers were tested using the online software IDT OligoAnalyzer 3.1, and the specificity of the primers and the probe were checked using NCBI’s Blastn. The primers and the probe were found not to form secondary structures or primer dimers, nor to hybridize to any other known sequence. The primers and the probe were manufactured by Thermo Fischer Scientific.
The RT-PCR assay was performed using the QIAGEN QuantiTech Master Mix.
Amplifications were done on a Applied Biosystems 7500 Real-Time PCR machine (Thermo Fischer Scientific) with the following conditions: 30 min at 50 °C, 15 min at 95 °C followed by 45 cycles of 94 °C/15 s and 60 °C/1 minute.
Results of the qPCR
To validate if the tentative virus could be disease causing, 17 fish with clinical symptoms and 20 fish without clinical symptoms from 4 different farms along the Norwegian coastline were tested with the LV1- qPCR assay. Extracted total RNA from kidney samples were used in the test.
In farms from Sogn og Fjordane, Nordland and Troms the fish had clinical signs of disease such as pale yellow liver, pale heart, pale gills, ascites in the abdominal cavity and some wounds in the abdominal region. In these tree farms, the LV1 Real Time assay detected relatively high amounts of the gene sequence the LV1 assay targeted, in all except from one fish. There are multiple factors that may have affected this one fish, the overall trends is clear positive. The farm from Møre og Romsdal had Healthy fish and now signs of disease or clinical symptoms, or LV. This confirms that the virus detected causes the observed symptoms.
Additional qPCR assays
We have designed 12 additional quantitative Real Time TaqMan assays targeting various regions of the genome, as described above for LV1.
Claims (20)
1. An isolated nucleic acid sequence originating from a virus in lumpsucker having a sequence selected from the group consisting of SEQ ID No 1-14, sequences being complementary to SEQ ID NO 1-14, and variants thereof being at least 70 % identical thereof.
2. An isolated nucleic acid sequence according to claim 1, characterized in that the sequence is at least 80 %, preferably 90%, more preferably 95 % identical with any of the sequences SEQ ID No 1-14, or any sequences being complementary to SEQ ID No 1-14.
3. A primer and/or probe comprising a sequence of at least 10 nucleotides, having a sequence selected from the group consisting of SEQ ID NO 1-14, sequences being complementary to SEQ ID NO 1-14, and variants being at least 70 % identical with any of the sequences SEQ ID NO 1-14 and sequences being complementary to SEQ ID NO 1-14.
4. A primer and/or probe according to claim 3, wherein said sequences are selected from the group consisting of SEQ ID NO 15-53, sequences being complementary to SEQ ID NO 15-53, and variants being at least 70 % identical with any of the sequences SEQ ID NO 15-53 and sequences being complementary to SEQ ID NO 15-53.
5. A primer and/or probe according to claim 3 or 4, wherein said sequence is at least 15 nucleotides long, or 20 nucleotides long.
6. A method for detection of a virus in a biological sample, characterized by comprising the following steps:
a) preparing a biological sample comprising nucleic acid sequences isolated from a biological sample for a reverse transcription reaction,
b) subjecting the mixture of a) to a polymerase chain reaction with a pair of primers according to claims 3-5, and
c) determining whether the binding of the primers to nucleotide sequences in the sample and amplification of the sequence between them have occurred indicating the presence of the virus in the sample tested.
7. A method according to claim 6, wherein the primers are selected from a group consisting for SEQ ID No 28-53.
8. A method for detection of a virus in a biological sample, characterized by comprising the following steps:
a) preparing a biological sample comprising nucleic acid sequences isolated from a biological sample for a reverse transcription reaction,
b) sequencing the mixture of a), and
c) comparing the resulting sequence with the sequence selected of the group consisting of SEQ ID No 1-14 and sequences being complementary to SEQ ID NO 1-14, wherein 70 % identity verifies presence of the virus in the biological sample tested.
9. A method according to claim 8, wherein the sequencing is performed by a method selected from the group consisting in Illumina (Solexa) sequencing, Roche 454 sequencing, Ion Torrent and SOLiD sequencing.
10. A method according to 8 or 9, wherein the sequence is at least 80 %, preferably 90%, more preferably 95 % identical with any of the sequences SEQ ID No 1-14 or sequences being complementary to SEQ ID No 1-14
11. Use of a nucleotide sequence comprising at the least 10 contiguous nucleotides of any of the sequences 1-53, or 10 contiguous nucleotides being complementary of any of the sequences 1-53, for establishing the existence of virus in a biological sample.
12. Use according to claim 11, wherein the nucleic acid sequence has a sequence selected from the group of SEQ ID No 1, or a sequence being complementary to the any of the sequences SEQ ID No 1.
13. A vector comprising a nucleic acid sequence according to any one of claims 1-5.
14. A host cell comprising a vector according to claim 13.
15. A DNA-vaccine comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO 1-14, and variants thereof being at least 70 % identical with any of the sequences of SEQ ID NO 1-14.
16. A recombinant protein encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NO 1-14, and variants thereof being at least 70 % identical with any of the sequences of SEQ ID NO 1-14.
17. A recombinant protein having an amino acid sequence according to SEQ ID No 54.
18. A recombinant vaccine comprising at least one recombinant protein according to claim 16 or 17.
19. An antibody specifically recognizing and specifically binding to a recombinant protein according to claim 16 or 17.
20. Diagnostic kit comprising at least one primer sequence according to any of claims 3-5.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NO20170739A NO344051B1 (en) | 2017-05-04 | 2017-05-04 | Novel virus in Fish and Method for detection |
PCT/NO2018/050118 WO2018203757A1 (en) | 2017-05-04 | 2018-05-03 | Novel virus in fish and a method for detection |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NO20170739A NO344051B1 (en) | 2017-05-04 | 2017-05-04 | Novel virus in Fish and Method for detection |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20170739A1 true NO20170739A1 (en) | 2018-11-05 |
NO344051B1 NO344051B1 (en) | 2019-08-26 |
Family
ID=62196668
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20170739A NO344051B1 (en) | 2017-05-04 | 2017-05-04 | Novel virus in Fish and Method for detection |
Country Status (2)
Country | Link |
---|---|
NO (1) | NO344051B1 (en) |
WO (1) | WO2018203757A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2551984B (en) * | 2016-06-30 | 2019-01-16 | Pharmaq As | Fish virus |
EP3693465A1 (en) * | 2019-02-05 | 2020-08-12 | Pharmaq AS | Novel fish coronavirus |
NO347379B1 (en) * | 2020-10-30 | 2023-10-02 | Patogen As | Novel fish virus |
Citations (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5610054A (en) * | 1992-05-14 | 1997-03-11 | Ribozyme Pharmaceuticals, Inc. | Enzymatic RNA molecule targeted against Hepatitis C virus |
US5739311A (en) * | 1995-06-07 | 1998-04-14 | Gen-Probe Incorporated | Enzymatic synthesis of phosphorothioate oligonucleotides using restriction endonucleases |
WO2000078341A1 (en) * | 1999-06-21 | 2000-12-28 | Murdoch Childrens Research Institute | A method for the prophylaxis and/or treatment of medical disorders |
WO2001007662A1 (en) * | 1999-07-22 | 2001-02-01 | Genaissance Pharmaceuticals, Inc. | Drug target isogenes: polymorphisms in the prostaglandin-endoperoxide synthase 2 gene |
US6194150B1 (en) * | 1995-07-07 | 2001-02-27 | Ribozyme Pharmaceuticals, Inc. | Nucleic acid based inhibition of CD40 |
WO2001025481A1 (en) * | 1999-10-04 | 2001-04-12 | Olympus Optical Co., Ltd. | Method of detecting nucleic acid |
WO2001077384A2 (en) * | 2000-04-07 | 2001-10-18 | Epigenomics Ag | Detection of single nucleotide polymorphisms (snp's) and cytosine-methylations |
WO2001085998A1 (en) * | 2000-05-05 | 2001-11-15 | Genaissance Pharmaceuticals, Inc. | Haplotypes of the crybb1 gene |
WO2001090415A2 (en) * | 2000-05-20 | 2001-11-29 | The Regents Of The University Of Michigan | Method of producing a dna library using positional amplification |
WO2002053774A2 (en) * | 2001-01-03 | 2002-07-11 | Henkel Kommanditgesellschaft Auf Aktien | Method for determining homeostasis of the skin |
WO2002053775A2 (en) * | 2000-12-28 | 2002-07-11 | Epidauros Biotechnologie Ag | Identification of genetic determinants of polymorphic cyp3a5 expression |
WO2002074799A2 (en) * | 2001-03-19 | 2002-09-26 | Bayer Cropscience S.A. | Pepsin-sensitive modified bacillus thuringiensis insecticidal toxin |
WO2003040369A2 (en) * | 2001-09-17 | 2003-05-15 | Molecular Engines Laboratories | Sequences involved in tumoral suppression, tumoral reversion, apoptosis and/or viral resistance phenomena and their use as medicines |
US20030147864A1 (en) * | 2001-12-18 | 2003-08-07 | Isis Pharmaceuticals Inc. | Antisense modulation of CD36L1 expression |
US20040101848A1 (en) * | 2002-11-23 | 2004-05-27 | Isis Pharmaceuticals Inc. | Modulation of glucose transporter-4 expression |
US20040102389A1 (en) * | 1995-10-26 | 2004-05-27 | Ribozyme Pharmaceuticals, Inc. | Nucleic acid-mediated treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R) |
WO2004045543A2 (en) * | 2002-11-14 | 2004-06-03 | Dharmacon, Inc. | Functional and hyperfunctional sirna |
WO2004059001A2 (en) * | 2002-12-20 | 2004-07-15 | Henkel Kommanditgesellschaft Auf Aktien | Method for determining markers of human facial skin |
WO2004059002A2 (en) * | 2002-12-20 | 2004-07-15 | Henkel Kommanditgesellschaft Auf Aktien | Method for determining the homeostasis of hairy skin |
US6818447B1 (en) * | 1995-10-26 | 2004-11-16 | Sirna Therapeutics, Inc. | Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor |
US6821724B1 (en) * | 1998-09-17 | 2004-11-23 | Affymetrix, Inc. | Methods of genetic analysis using nucleic acid arrays |
WO2005021745A1 (en) * | 2003-08-22 | 2005-03-10 | Nihon University | Hepatocellular cancer-associated gene |
WO2005035545A2 (en) * | 2003-10-02 | 2005-04-21 | Epoch Biosciences, Inc. | Single nucleotide polymorphism analysis of highly polymorphic target sequences |
WO2006034879A2 (en) * | 2004-09-30 | 2006-04-06 | Epigenomics Ag | Epigenetic methods and nucleic acids for the detection of lung cell proliferative disorders |
JP2008048612A (en) * | 2006-08-22 | 2008-03-06 | Bio Taxol:Kk | Glycosyltransferase gene |
WO2008141449A1 (en) * | 2007-05-18 | 2008-11-27 | National Research Council Of Canada | Single-domain antibodies and heavy chain antibody against egfr and uses thereof |
WO2008109487A9 (en) * | 2007-03-02 | 2008-12-24 | Mdrna Inc | Nucleic acid compounds for inhibiting mme gene expression and uses thereof |
US20090306180A1 (en) * | 2006-05-05 | 2009-12-10 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating expression apob |
CN101798341A (en) * | 2009-02-11 | 2010-08-11 | 中国科学院植物研究所 | Heat shock factor protein relevant to resistance of plants as well as coding gene and application thereof |
WO2012170438A2 (en) * | 2011-06-06 | 2012-12-13 | Amgen Inc. | HUMAN ANTIGEN BINDING PROTEINS THAT BIND TO A COMPLEX COMPRISING β-KLOTHO AND AN FGF RECEPTOR |
WO2013173599A1 (en) * | 2012-05-16 | 2013-11-21 | Rana Therapeutics, Inc. | Compositions and methods for modulating hemoglobin gene family expression |
CN103484545A (en) * | 2013-09-16 | 2014-01-01 | 新疆师范大学 | Garlic germplasm resource RAPD genetic diversity analysis method |
WO2015038634A2 (en) * | 2013-09-13 | 2015-03-19 | Rutgers, The State University Of New Jersey | Multiplex diagnostic assay for lyme disease and other tick-borne diseases |
CN104894237A (en) * | 2015-04-30 | 2015-09-09 | 中国农业大学 | Integrated fluidic chip for identification of fruit fly type and use thereof |
EP3263590A1 (en) * | 2016-06-30 | 2018-01-03 | Pharmaq AS | Fish virus |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012177639A2 (en) * | 2011-06-22 | 2012-12-27 | Alnylam Pharmaceuticals, Inc. | Bioprocessing and bioproduction using avian cell lines |
JP5960917B1 (en) * | 2013-02-07 | 2016-08-02 | チャイナ ナショナル シード グループ カンパニー リミテッド | Rice whole genome breeding chip and its application |
WO2016075277A1 (en) * | 2014-11-14 | 2016-05-19 | Patogen Analyse As | Novel fish virus and method for detection |
-
2017
- 2017-05-04 NO NO20170739A patent/NO344051B1/en unknown
-
2018
- 2018-05-03 WO PCT/NO2018/050118 patent/WO2018203757A1/en active Application Filing
Patent Citations (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5610054A (en) * | 1992-05-14 | 1997-03-11 | Ribozyme Pharmaceuticals, Inc. | Enzymatic RNA molecule targeted against Hepatitis C virus |
US5739311A (en) * | 1995-06-07 | 1998-04-14 | Gen-Probe Incorporated | Enzymatic synthesis of phosphorothioate oligonucleotides using restriction endonucleases |
US6194150B1 (en) * | 1995-07-07 | 2001-02-27 | Ribozyme Pharmaceuticals, Inc. | Nucleic acid based inhibition of CD40 |
US6818447B1 (en) * | 1995-10-26 | 2004-11-16 | Sirna Therapeutics, Inc. | Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor |
US20040102389A1 (en) * | 1995-10-26 | 2004-05-27 | Ribozyme Pharmaceuticals, Inc. | Nucleic acid-mediated treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R) |
US6821724B1 (en) * | 1998-09-17 | 2004-11-23 | Affymetrix, Inc. | Methods of genetic analysis using nucleic acid arrays |
WO2000078341A1 (en) * | 1999-06-21 | 2000-12-28 | Murdoch Childrens Research Institute | A method for the prophylaxis and/or treatment of medical disorders |
WO2001007662A1 (en) * | 1999-07-22 | 2001-02-01 | Genaissance Pharmaceuticals, Inc. | Drug target isogenes: polymorphisms in the prostaglandin-endoperoxide synthase 2 gene |
WO2001025481A1 (en) * | 1999-10-04 | 2001-04-12 | Olympus Optical Co., Ltd. | Method of detecting nucleic acid |
WO2001077384A2 (en) * | 2000-04-07 | 2001-10-18 | Epigenomics Ag | Detection of single nucleotide polymorphisms (snp's) and cytosine-methylations |
WO2001085998A1 (en) * | 2000-05-05 | 2001-11-15 | Genaissance Pharmaceuticals, Inc. | Haplotypes of the crybb1 gene |
WO2001090415A2 (en) * | 2000-05-20 | 2001-11-29 | The Regents Of The University Of Michigan | Method of producing a dna library using positional amplification |
WO2002053775A2 (en) * | 2000-12-28 | 2002-07-11 | Epidauros Biotechnologie Ag | Identification of genetic determinants of polymorphic cyp3a5 expression |
WO2002053774A2 (en) * | 2001-01-03 | 2002-07-11 | Henkel Kommanditgesellschaft Auf Aktien | Method for determining homeostasis of the skin |
WO2002074799A2 (en) * | 2001-03-19 | 2002-09-26 | Bayer Cropscience S.A. | Pepsin-sensitive modified bacillus thuringiensis insecticidal toxin |
WO2003040369A2 (en) * | 2001-09-17 | 2003-05-15 | Molecular Engines Laboratories | Sequences involved in tumoral suppression, tumoral reversion, apoptosis and/or viral resistance phenomena and their use as medicines |
US20030147864A1 (en) * | 2001-12-18 | 2003-08-07 | Isis Pharmaceuticals Inc. | Antisense modulation of CD36L1 expression |
WO2004045543A2 (en) * | 2002-11-14 | 2004-06-03 | Dharmacon, Inc. | Functional and hyperfunctional sirna |
US20040101848A1 (en) * | 2002-11-23 | 2004-05-27 | Isis Pharmaceuticals Inc. | Modulation of glucose transporter-4 expression |
WO2004059002A2 (en) * | 2002-12-20 | 2004-07-15 | Henkel Kommanditgesellschaft Auf Aktien | Method for determining the homeostasis of hairy skin |
WO2004059001A2 (en) * | 2002-12-20 | 2004-07-15 | Henkel Kommanditgesellschaft Auf Aktien | Method for determining markers of human facial skin |
WO2005021745A1 (en) * | 2003-08-22 | 2005-03-10 | Nihon University | Hepatocellular cancer-associated gene |
WO2005035545A2 (en) * | 2003-10-02 | 2005-04-21 | Epoch Biosciences, Inc. | Single nucleotide polymorphism analysis of highly polymorphic target sequences |
WO2006034879A2 (en) * | 2004-09-30 | 2006-04-06 | Epigenomics Ag | Epigenetic methods and nucleic acids for the detection of lung cell proliferative disorders |
US20090306180A1 (en) * | 2006-05-05 | 2009-12-10 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating expression apob |
JP2008048612A (en) * | 2006-08-22 | 2008-03-06 | Bio Taxol:Kk | Glycosyltransferase gene |
WO2008109487A9 (en) * | 2007-03-02 | 2008-12-24 | Mdrna Inc | Nucleic acid compounds for inhibiting mme gene expression and uses thereof |
WO2008141449A1 (en) * | 2007-05-18 | 2008-11-27 | National Research Council Of Canada | Single-domain antibodies and heavy chain antibody against egfr and uses thereof |
CN101798341A (en) * | 2009-02-11 | 2010-08-11 | 中国科学院植物研究所 | Heat shock factor protein relevant to resistance of plants as well as coding gene and application thereof |
WO2012170438A2 (en) * | 2011-06-06 | 2012-12-13 | Amgen Inc. | HUMAN ANTIGEN BINDING PROTEINS THAT BIND TO A COMPLEX COMPRISING β-KLOTHO AND AN FGF RECEPTOR |
WO2013173599A1 (en) * | 2012-05-16 | 2013-11-21 | Rana Therapeutics, Inc. | Compositions and methods for modulating hemoglobin gene family expression |
WO2015038634A2 (en) * | 2013-09-13 | 2015-03-19 | Rutgers, The State University Of New Jersey | Multiplex diagnostic assay for lyme disease and other tick-borne diseases |
CN103484545A (en) * | 2013-09-16 | 2014-01-01 | 新疆师范大学 | Garlic germplasm resource RAPD genetic diversity analysis method |
CN104894237A (en) * | 2015-04-30 | 2015-09-09 | 中国农业大学 | Integrated fluidic chip for identification of fruit fly type and use thereof |
EP3263590A1 (en) * | 2016-06-30 | 2018-01-03 | Pharmaq AS | Fish virus |
Non-Patent Citations (9)
Title |
---|
GenBank AI154875 https://www.ncbi.nlm.nih.gov/nucest/AI154875 1998.09.30, [Hentet 2018.10.01 fra internett]. , Dated: 01.01.0001 * |
Genbank BD080356 https://www.ncbi.nlm.nih.gov/nuccore/BD080356 2002.08.27, [Hentet 2018.10.01 fra internett]. , Dated: 01.01.0001 * |
GenBank BD165765, https://www.ncbi.nlm.nih.gov/nuccore/BD165765 2003.01.17, [Hentet 2018.10.01 fra internett]. , Dated: 01.01.0001 * |
Genbank BD201823 https://www.ncbi.nlm.nih.gov/nuccore/BD201823 2005.11.04 [Hentet 2018.10.01 fra internett]. , Dated: 01.01.0001 * |
Genebank AAQ15050 Tamana Bat Virus https://www.ncbi.nlm.nih.gov/protein/AAQ15050, Dated: 01.01.0001 * |
Glosvik, H og Breck, O., Helserelaterte utfordringer i produksjon av rensefisk, Erfaringer fra Marine Harvest, http://www.fhf.no/media/157686/04_170209_helse_produksjon_rensefiskkonf_trondheim.pdf Dokumentet er lenket fra http://www.fhf.no/nyheter/arrangementer/rensefiskkonferansen-2017/ sist oppdatert 2017.03.08, Dated: 01.01.0001 * |
Gulla, S. Veterinærinstituttet, Helsestatus for rensefisk i 2016, http://www.fhf.no/media/157605/07_helsestatus_for_rensefisk_sg2.pdf Dokumentet er lenket fra http://www.fhf.no/nyheter/arrangementer/rensefiskkonferansen-2017/ sist oppdatert 2017.03.08, Dated: 01.01.0001 * |
Hjeltnes, B. et al., Fiskehelserapporten 2016, Veterinærinstituttets rapportserie nr. 4/2017, publisert 2017.03.06. https://www.vetinst.no/rapporter-og-publikasjoner/rapporter/2017/fiskehelserapporten-2016, Dated: 01.01.0001 * |
Vestervik, N. F. et al., Lumpfish Flavivirus – Kunnskap og utfordringer, Pharmaq Analytiq AS, https://www.pharmaq-analytiq.com/kunnskap/rensefisk/lumpfish-flavivirus/ Udatert, men er i hht. kyst.no 2017.08.22 publisert i anledning messen Aqua nor august 2017 http://kyst.no/nyheter/rognkjeks-flavivirus-kunnskap-og-utfordringer/, Dated: 01.01.0001 * |
Also Published As
Publication number | Publication date |
---|---|
WO2018203757A1 (en) | 2018-11-08 |
NO344051B1 (en) | 2019-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Mahmood et al. | Isolation and molecular characterization of Sul/01/09 avian infectious bronchitis virus, indicates the emergence of a new genotype in the Middle East | |
Sun et al. | Sensitive and rapid detection of infectious hypodermal and hematopoietic necrosis virus (IHHNV) in shrimps by loop-mediated isothermal amplification | |
Kuta et al. | Predominance of bovine viral diarrhea virus 1b and 1d subtypes during eight years of survey in Poland | |
Bellière et al. | Genetic comparison among dolphin morbillivirus in the 1990–1992 and 2006–2008 Mediterranean outbreaks | |
WO2018203757A1 (en) | Novel virus in fish and a method for detection | |
Saeed et al. | RT-PCR evaluation for identification and sequence analysis of foot-and-mouth disease serotype O from 2006 to 2007 in Punjab, Pakistan | |
WO2009098789A1 (en) | Method of detecting pathogenic virus in crustacean by lamp method and reagent kit for detection | |
Fellahi et al. | Phylogenetic analysis of avian infectious bronchitis virus S1 glycoprotein regions reveals emergence of a new genotype in Moroccan broiler chicken flocks | |
Nyaga et al. | Complete genome analyses of the first porcine rotavirus group H identified from a South African pig does not provide evidence for recent interspecies transmission events | |
WO2016075277A1 (en) | Novel fish virus and method for detection | |
Jorquera et al. | Chilean IPNV isolates: Robustness analysis of PCR detection | |
JP2010501178A (en) | Shrimp pathogen diagnostic sequence | |
Rovaris et al. | Phylogenetic analyses of the hemagglutinin gene of wild-type strains of canine distemper virus in southern Brazil | |
KR101742470B1 (en) | Method for Differentiating between Rift Valley Fever Virus and its Vaccine(Clone 13), and Primer Set and Probe Used for the Differentiation | |
JP5483173B2 (en) | Shrimp detection primer set | |
Ranjan et al. | Vp5 gene based molecular characterization of bluetongue virus 9 from South India | |
GB2377017A (en) | Detection of foot and mouth disease virus | |
Abernathy et al. | Gene expression profiling of a fish parasite Ichthyophthirius multifiliis: Insights into development and senescence-associated avirulence | |
Ranjan et al. | Molecular characterization of segment 6 of bluetongue serotype 16 of sheep origin from India | |
Hedayati et al. | Detection of avian reoviruses causing tenosynovitis in breeder flocks in Iran by reverse transcription-polymerase chain reaction (RT-PCR) and restriction enzyme fragment length polymorphism (RFLP) | |
NO344698B1 (en) | Novel fish virus | |
KR101728421B1 (en) | Markers for identitying fish species contained in surimi products | |
Kerfua et al. | Molecular characterization of serotype O foot-andmouth disease virus from pigs: Implications for multispecies approach to disease control in Uganda | |
NO347379B1 (en) | Novel fish virus | |
Siddique et al. | Molecular characterization of foot-and-mouth disease virus type O from wild pig in Bangladesh |